Loading...
•
Mar 31, 2025
Zomedica Q1 2025 Earnings Report
Zomedica reported a Q1 net loss of $63.8 million due to a $55.8 million non-cash impairment charge, despite achieving record revenue of $6.5 million.
Key Takeaways
Zomedica delivered record Q1 revenue led by growth in therapeutic devices and consumables, but posted a significant net loss driven by a large impairment charge.
Revenue reached $6.5 million, a 4% increase year-over-year.
Gross margin improved to 68%, up from 66% in Q1 2024.
Net loss expanded to $63.8 million due to a $55.8 million impairment.
Adjusted EBITDA loss was $5.7 million, slightly higher than Q1 2024.
Revenue by Segment
Forward Guidance
Zomedica expressed confidence in accelerating adoption of its product portfolio, supported by strong balance sheet and international growth.
Positive Outlook
- Continued growth of PulseVet and TRUFORMA product lines.
- Introduction of new VETIGEL product line.
- Expansion in international markets with 32% YoY growth.
- Strong gross margin performance at 68%.
- Solid liquidity position with $65M in cash and equivalents.
Challenges Ahead
- Significant net loss driven by impairment charge.
- Diagnostics segment revenue declined 25% YoY.
- Capital equipment revenue declined due to lack of large distribution orders.
- Adjusted EBITDA loss increased slightly from Q1 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...